DRUG.CNDRUG.CN
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | -1397.37% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | -1496.84% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | -2380.51% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | -1536.89% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | -1594.95% | +0.00% |
| Weighted Average Shares Growth | +18.34% | +60.46% | +57.68% | +58.70% | +60.57% |
| Weighted Average Shares Diluted Growth | +23.25% | +72.84% | +57.68% | +52.37% | +54.18% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | -1559.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | -1559.00% | +0.00% |
| Receivables Growth | +35.81% | +48.80% | -57.78% | +1481.77% | +722.46% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -11.26% | +747.95% | +764.61% | +736.23% | +1282.92% |
| Book Value per Share Growth | -29.10% | +497.38% | +521.81% | +435.47% | +822.90% |
| Debt Growth | +61.74% | +234.90% | +379.66% | +906.21% | +5.73% |
| R&D Expense Growth | -61.88% | -14.70% | +2336.85% | +0.00% | +1049.90% |
| SG&A Expenses Growth | -23.55% | +34.83% | +56.29% | +84.61% | +115.49% |